[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655691":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":11,"studyPopulation":11,"armGroups":44,"interventions":55,"overallOfficials":11,"centralContacts":65,"locations":71,"responsibleParty":203,"collaborators":11,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":11,"eligibilityCriteria":210,"healthyVolunteers":207,"sex":211,"minAge":212,"maxAge":213,"enrollmentInfo":214,"targetDuration":11,"studyType":217,"phases":218,"briefSummary":220,"conditions":221,"keywords":11,"overallStatus":223,"whyStopped":11,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},{"fullName":5,"class":6},"Bisirna Therapeutics (Suzhou) Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":36},[9],{"measure":10,"description":11,"timeFrame":12},"The proportion of patients with sustained hemoglobin levels ≥ 120 g\u002FL among those without RBC transfusion (defined as no red blood cell infusion after W2 to W26).",null,"between Week 2 and Week 26",[14,17,19,21,23,25,27,29,32,34],{"measure":15,"description":11,"timeFrame":16},"Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥ 20 g\u002FL assessed among those without RBC transfusion (defined as no red blood cell infusion after W2 to W26).","between Week 20 and Week 26",{"measure":18,"description":11,"timeFrame":16},"The proportion of patients with hemolysis controlled (defined as LDH \u003C 1.5 ULN) among those without RBC transfusion",{"measure":20,"description":11,"timeFrame":16},"Change (Expressed as Percentages) in Hb level from baseline",{"measure":22,"description":11,"timeFrame":12},"The proportion of patients without RBC transfusion",{"measure":24,"description":11,"timeFrame":16},"Change in reticulocyte count from baseline",{"measure":26,"description":11,"timeFrame":16},"Change in Total bilirubin count from baseline",{"measure":28,"description":11,"timeFrame":16},"Change in FACIT-F score from baseline",{"measure":30,"description":11,"timeFrame":31},"The Clinical BTH Rate","between Day 1 and Week 26",{"measure":33,"description":11,"timeFrame":31},"The Major Adverse Vascular Events Rate",{"measure":35,"description":11,"timeFrame":31},"Incidence and severity of AEs",[37],{"measure":35,"description":11,"timeFrame":31},{"allocation":39,"interventionModel":40,"interventionModelDescription":11,"primaryPurpose":41,"observationalModel":11,"timePerspective":11,"maskingInfo":42},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":43,"maskingDescription":11,"whoMasked":11},"NONE",[45,50],{"label":46,"type":47,"description":11,"interventionNames":48},"Cohort1","EXPERIMENTAL",[49],"Drug: VSA012",{"label":51,"type":52,"description":11,"interventionNames":53},"Cohort2","ACTIVE_COMPARATOR",[54],"Drug: Eculizumab (Soliris®)",[56,61],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":11},"DRUG","VSA012","VSA012 Injection",[46],{"type":57,"name":62,"description":63,"armGroupLabels":64,"otherNames":11},"Eculizumab (Soliris®)","Eculizumab injection",[51],[66],{"name":67,"role":68,"phone":69,"phoneExt":11,"email":70},"Charlene Si","CONTACT","+86-021-6107 5030","charlene.si@bisirna.com",[72,89,98,106,114,122,131,139,147,155,163,172,180,189],{"facility":73,"status":11,"city":74,"state":75,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Peking Union Medical College Hospital","Beijing","Beijing Municipality","China","CN",{"type":79,"coordinates":80},"Point",[81,82],116.39723,39.9075,{"lat":82,"lon":81},[85],{"name":86,"role":68,"phone":87,"phoneExt":11,"email":88},"Bing Han","010-69151188","Hanbing-li@sina.com.cn",{"facility":90,"status":11,"city":91,"state":92,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"Jilin","Jilin City","Changchun",{"type":79,"coordinates":94},[95,96],126.5608,43.84652,{"lat":96,"lon":95},{"facility":99,"status":11,"city":99,"state":100,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":101,"geoPoint":105,"contacts":11},"Quanzhou","Fujian",{"type":79,"coordinates":102},[103,104],118.58583,24.91389,{"lat":104,"lon":103},{"facility":107,"status":11,"city":107,"state":108,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":109,"geoPoint":113,"contacts":11},"Guangzhou","Guangdong",{"type":79,"coordinates":110},[111,112],113.25,23.11667,{"lat":112,"lon":111},{"facility":115,"status":11,"city":115,"state":116,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":117,"geoPoint":121,"contacts":11},"Nanning","Guangxi",{"type":79,"coordinates":118},[119,120],108.31667,22.81667,{"lat":120,"lon":119},{"facility":123,"status":11,"city":124,"state":125,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":126,"geoPoint":130,"contacts":11},"Ha'erbin","Harbin","Heilongjiang",{"type":79,"coordinates":127},[128,129],126.65,45.75,{"lat":129,"lon":128},{"facility":132,"status":11,"city":132,"state":133,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":134,"geoPoint":138,"contacts":11},"Zhengzhou","Henan",{"type":79,"coordinates":135},[136,137],113.64861,34.75778,{"lat":137,"lon":136},{"facility":140,"status":11,"city":140,"state":141,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":142,"geoPoint":146,"contacts":11},"Wuhan","Hubei",{"type":79,"coordinates":143},[144,145],114.26667,30.58333,{"lat":145,"lon":144},{"facility":148,"status":11,"city":148,"state":149,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":150,"geoPoint":154,"contacts":11},"Changsha","Hunan",{"type":79,"coordinates":151},[152,153],112.97087,28.19874,{"lat":153,"lon":152},{"facility":156,"status":11,"city":156,"state":157,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":158,"geoPoint":162,"contacts":11},"Nantong","Jiangsu",{"type":79,"coordinates":159},[160,161],120.87472,32.03028,{"lat":161,"lon":160},{"facility":164,"status":11,"city":165,"state":166,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":167,"geoPoint":171,"contacts":11},"Xi'an","Xi’an","Shanxi",{"type":79,"coordinates":168},[169,170],113.52486,35.99785,{"lat":170,"lon":169},{"facility":173,"status":11,"city":173,"state":174,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":175,"geoPoint":179,"contacts":11},"Chengdu","Sichuan",{"type":79,"coordinates":176},[177,178],104.06667,30.66667,{"lat":178,"lon":177},{"facility":181,"status":11,"city":182,"state":183,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":184,"geoPoint":188,"contacts":11},"Institute of Hematology, Chinese Academy of Medical Sciences","Tianjin","Tianjin Municipality",{"type":79,"coordinates":185},[186,187],117.17667,39.14222,{"lat":187,"lon":186},{"facility":190,"status":11,"city":191,"state":192,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"The First Affiliated Hospital of Zhejiang University School of Medicine","Hangzhou","Zhejiang",{"type":79,"coordinates":194},[195,196],120.16142,30.29365,{"lat":196,"lon":195},[199],{"name":200,"role":68,"phone":201,"phoneExt":11,"email":202},"Hongyan Tong","0571-87236114","hongyantong@aliyun.com",{"type":204,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100655691","phase-3-a-multicenter-randomized-open-label-positive-controlled-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-vsa012-injection-in-participants-with-paroxysmal-nocturnal-hemoglobinuria-who-are-naive-to-complement-inhibitor-therapy-100655691",false,"NCT07816237","A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy","Inclusion Criteria:\n\n* Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg\u002Fm2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size≥10%.\n* Mean hemoglobin level \\\u003C100 g\u002FL at screening.\n* LDH \\> 1.5 x Upper Limit of Normal (ULN) at screening.\n* Vaccination against Neisseria meningitidis infection is required prior to the\n* start of study treatment. If not received previously, vaccination against\n* Streptococcus pneumoniae and Haemophilus influenzae infections should be given.\n\nExclusion Criteria:\n\n* Known or suspected hereditary or acquired complement deficiency;\n* Presence or suspicion of a systemic active bacterial, viral, or fungal infection\n* History of infection with capsular bacteria (e.g., meningococcus, pneumococcus, etc.)\n* Patients with reticulocytes \\\u003C100x10\\^9\u002FL; platelets \\\u003C30x10\\^9\u002FL; neutrophils \\\u003C0.5x10\\^9\u002FL.\n* Positive of HIV, HBsAg or HCVAb.\n* History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus.\n* Previous splenectomy.\n* A history of malignancy within 5 years before screening","ALL","18 Years","75 Years",{"count":215,"type":216},70,"ESTIMATED","INTERVENTIONAL",[219],"PHASE3","A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.",[222],"Paroxysmal Nocturnal Hemoglobinuria, PNH","NOT_YET_RECRUITING","2026-09-09",{"date":226,"type":227},"2026-09-11","ACTUAL",{"date":229,"type":216},"2026-10-29",{"date":231,"type":216},"2029-12-31",{"name":5,"class":6},14]